ASH 2023 | Ruxolitinib plus venetoclax in heavily pretreated patients with R/R AML
Uma Borate
• 8 Dec 2023
Uma Borate, MD, The Ohio State University, Columbus, OH, outlines the Phase I trial (NCT03874052) evaluating the use of the JAK2 inhibitor ruxolitinib with the BCL2 inhibitor venetoclax following the demonstration of ex vivo efficacy. This oral intervention was effective and well tolerated in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) who were heavily pretreated. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
